Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2003
10/21/2003US6635678 Topical application of phenylephrine
10/21/2003US6635676 Non-toxic antimicrobial compositions and methods of use
10/21/2003US6635671 Compounds which affect mRNA stability and uses therefor
10/21/2003US6635669 Kinase inhibitor; benign prostatic hyperplasia
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635640 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
10/21/2003US6635629 For therapy and prophylaxis of inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias
10/21/2003US6635473 Isolated nucleic acid encoding a fibrinogen-binding protein; useful in prevention, diagnosis and treatment of infections; can be administered to wounds or for coating prosthetics to inhibit binding of the bacteria
10/21/2003US6635451 Conversion of dihomo-gamma linolenic acid (DGLA) to arachidonic acid and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA); Delta 6 desaturase and Delta 5 desaturase
10/21/2003US6635287 Obtaining an extract from producer cells derived from an organism which is xenogeneic to said target cells and which is capable of entering into a dormant state
10/21/2003US6635252 Antibodies to superoxide dismutase-4
10/21/2003US6635251 Eotaxin-specific antibodies
10/21/2003CA2310318C Pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl] ethoxy]acetic acid dihydrochloride
10/21/2003CA2251790C Methods of regulating skin appearance with vitamin b3 compound
10/21/2003CA2237401C Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
10/16/2003WO2003085377A2 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003WO2003085072A1 Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
10/16/2003WO2003084966A1 Oxazolidinone derivatives
10/16/2003WO2003084964A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
10/16/2003WO2003084961A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003WO2003084955A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084950A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
10/16/2003WO2003084949A1 Pyridinoylpiperidines as 5-ht1f agonists
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084915A1 Novel thyroid receptor ligands
10/16/2003WO2003084565A2 Ve-ptp as regulator of ve-cadherin mediated processes or disorders
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084553A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
10/16/2003WO2003084549A1 Hormone replacement therapy
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003084485A1 Composition for cell proliferation
10/16/2003WO2003068813A3 Group b streptococcus antigen
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003059282A3 Human monoclonal antibodies against cd30
10/16/2003WO2003057152A3 Hair follicle growth
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003047533A3 Composition for treating the surface of the skin
10/16/2003WO2003041660A3 Solubilized topoisomerase poisons
10/16/2003WO2003039478A3 Method and apparatus for the stimulation of hair growth
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003030814A3 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against uvb rays
10/16/2003WO2003022218A3 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
10/16/2003WO2003015494A3 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/16/2003WO2003013461A3 Cosmetic composition and method of treating skin
10/16/2003WO2003013427A3 A method for preparing fluticasone derivatives
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002100826A3 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002076939A3 Cysteine protease inhibitors
10/16/2003WO2002055101A9 Storage stable powder compositions of interleukin-4 receptor
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003WO2002024307A3 Reducing the content of particular cell types in a biological sample
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195367 Method for preparing a fatty substance ester and use thereof in pharmaceutics, cosmetics or food industry
10/16/2003US20030195263 Use of 1,2-decandiol for combating germs causing body odour
10/16/2003US20030195251 For therapy of psychiatric, pain and other disorders
10/16/2003US20030195250 Method for photodynamic therapy and applicator for carrying out said therapy
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195238 Enzyme inhibitors
10/16/2003US20030195230 Substituted amine derivatives and methods of use
10/16/2003US20030195222 Substituted pyrimidinones and pyrimidinthiones
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195215 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors
10/16/2003US20030195212 An amide derivatives for treating obesity, anorexia, inflammation, mental diseases associated with the melanocyte stimulating hormones
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195179 Redispersibility comprising polyvinylpyrrolidone and a water-soluble anionic macromolecular compound which are added to prevent a hardly soluble drug from adhering to a container and forming aggregates
10/16/2003US20030195176 Vitamin d derivatives
10/16/2003US20030195172 Novel phosphonic acid compounds as inhibitors of serine proteases
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195160 Sodium channel blockers
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030195156 Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases
10/16/2003US20030194802 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194456 Extract of the leaves and/or stem of Argemone mexicana plant for treatment of psoriasis and related biochemical and immunological disorders
10/16/2003US20030194415 Film-forming compositions and methods
10/16/2003CA2694410A1 Pyridinoylpiperidines as 5-ht1f agonists
10/16/2003CA2481976A1 Novel thyroid receptor ligands
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481463A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480482A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
1 ... 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 ... 1065